Betahistine is indicated for the management of Ménière’s disease and Ménière-like syndromes, which are characterized by recurrent episodes of vertigo, tinnitus, and progressive hearing loss, often accompanied by nausea and vomiting.

Pregnancy: The safety of betahistine during pregnancy has not been fully established. It should be used only if the potential benefits outweigh the risks.

Lactation: Betahistine is excreted in breast milk at concentrations similar to plasma. The effects on the infant are unknown.

Caution is advised in patients with a history of peptic ulcer due to possible dyspepsia. It should also be used carefully in patients with bronchial asthma.

Patients with allergic conditions such as urticaria, rash, or allergic rhinitis should be monitored, as symptoms may worsen. Caution is required in patients with severe hypotension.

Patients with rare hereditary conditions such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should avoid this medication.

Effects on driving and machinery: Rare cases of drowsiness have been reported. Patients experiencing such effects should avoid driving or operating machinery.

Symptoms of overdose may include nausea, vomiting, indigestion, ataxia, and seizures. Severe complications such as convulsions or cardiopulmonary effects may occur in cases of intentional overdose, especially when combined with other drugs. There is no specific antidote. Management includes gastric lavage and symptomatic treatment.

Drugs used in Ménière’s disease.

Store below 30°C, protected from light and moisture. Keep out of reach of children.